Clinical Trial: Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Brief Summary: This is a extension study of CSTI571B1201 study
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: To study the antineoplastic effect of the investigational drug.
Original Primary Outcome:
Current Secondary Outcome: To study the safety and pharmacokinetics of the investigational drug.
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: October 9, 2005
Date Started: September 2002
Date Completion:
Last Updated: April 29, 2012
Last Verified: April 2012